We use cookies for a better user experience. Read our Privacy Policy

I Agree

Antiviral Drugs Market Insights, 2016-2024

Antiviral Drugs Market (Disease Indication - Hepatitis Virus Infection, HIV Infection, and Respiratory Virus Infection; Product Type - Branded Drugs and Generic Drugs; Distribution Channels - Hospital Pharmacy Store, Retail Pharmacy Store, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

Antiviral Drugs Market - Snapshot

Antiviral drugs refer to those prescription medicines that are capable of fighting against flu viruses in one’s body. Antiviral drugs could include intravenous solutions, an inhaled powder, liquid, or pills. However, antiviral drugs cannot be purchased just over-the-counter, one would need a prescription for obtaining such drugs. The global antiviral drugs market is likely to observe considerable growth due to the rising incidences of viral infections.

As coronavirus spreads at an exponential rate and the number of deaths crosses 74,000 worldwide, efforts are being made to lessen transmission through standard public health interventions. These interventions are based on tracing of contacts and isolation of cases. So far, there is no drug or vaccine to contain the spread of the pandemic worldwide. However, researchers and doctors have observed that antiviral drugs administered shortly after the onset of symptoms can diminish the infectiousness to others through diminished viral shredding in the patient’s respiratory secretions. The global antiviral drugs market is predicted to observe immense opportunity in the exponential spread of coronavirus. Besides, novel antiviral drugs, Tilorone and Remdesivir, have already come up as two of the most promising drugs for COVID-19 treatment, according to the researchers.

Rise in the Prevalence of Chronic Diseases to Support Demand of these Drugs

Rise in the research and development activities for development of newer and more advanced formulations is likely to further drive the demand for antiviral drugs in the near future. Many serious diseases could cause viral infections as their side effects. Such viral infection causing diseases are

  • HIV
  • Cancer
  • Respiratory diseases
  • Diabetes

As such, increased prevalence of these diseases are likely to increase the prevalence of viral infections thereby driving the demand for antiviral drugs. Apart from that, presence of sound healthcare infrastructure in several parts of the world is predicted to foster growth of the global antiviral drugs market in the years to come.

Global Antiviral Drugs Market – Overview

In recent years, there has been a considerable demand for antiviral drugs all across the globe. A large number of people are relying on these drugs to treat several diseases. A few years ago, the same population base relied on home remedies to cure basic diseases and infections. This kept these antiviral drugs market developing at a sluggish rate. However, in the past few years, technological advancements as well as advancements in the medical sciences have created a huge availability of these drugs. Previously, antiviral drugs were some sort of luxury. But with these developments, the production rate doubled up and these medicines became easily accessible to common masses. Naturally, the reliance over home remedies and cure dwindled as there came the availability of medically proven, more effective drugs. Furthermore, with the mass production or availability of these antiviral drugs, they also become cost effective. This only added to their popularity. Thus, the global antiviral drugs market has experienced a tremendous growth in recent years.

A new research report by Transparency Market Research on the global antiviral drugs market provide all the necessary insights and information required for formulation precise marketing strategies. According to the research report, the global market for antiviral drugs will exhibit a healthy CAGR of 6.40% over the course of the given forecast period of 2016 to 2024. The market is projected to reach a valuation worth US$82.9 bn by the end of the forecast period in 2024.

antiviral drugs market

Targeted Efforts towards Better Global Healthcare to Drive Market Growth

There are various reasons behind getting infected by a viral infections. At times, the infection may also be a side effect of some other medical treatment. Viral infections are common side effect of the treatment for diseases such as respiratory disorders, HIV, diabetes, and cancer among others. Because of the growing prevalence of these major diseases, there has been a growing demand for antiviral drugs. Naturally, this has helped in pushing the growth of the global antiviral drugs market to newer heights. In addition to this, with economical, sociological, and technological advancements, considerable efforts have been made towards achieving a strong and robust healthcare infrastructure across the globe. Though we are far from perfection, we can take solace in the fact that these consolidated and targeted efforts are only expected to grow in the future. This has had a profound impact on the development of the global antiviral drugs market. With targeted efforts from organizations such as Red Cross and World Health Organization, the spread and reach of antiviral drugs has grown exponentially and has thus helped in the overall growth of the global market.

Early Availability of New Drugs is Pushing Growth of North America Market

In terms of geographical segmentation, the global market for antiviral drugs is divided into five key regions viz. Asia Pacific, Middle East and Africa, North America, Europe, and Latin America. Of these, the growth of the market is maximum in North America. The presence of strong healthcare infrastructure and early access to latest medications and medical technology are some of the key factors for the growth of the antiviral drugs market in North America. Moreover, several new drugs are already in the production pipeline that will further strengthen the growth of the regional market.

Asia Pacific and Africa regions are showing great promise for the development of their respective antiviral drugs market. Growing prevalence of viral diseases such as malaria, dengue, chikungunya, and other deadly viral diseases is prompting an ever increasing demand for these antiviral drugs from these regions.

Some of the key players in the global antiviral drugs market include names such as Merck & Co. Inc., Johnson and Johnson, Schering-Plough Corporation, AbbVie Inc., and AstraZeneca Plc. among others.

The global antiviral drugs market is segmented as follows: 

By Disease Indication

  • Hepatitis Virus Infection
  • HIV Infection
  • Respiratory Virus Infection
  • Others 

By Product Type

  • Branded Drugs
  • Generic Drugs 

By Distribution Channels

  • Hospital Pharmacy Store
  • Retail Pharmacy Store
  • Online Pharmacy 

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa 
Antiviral Drugs Market Insights, 2016-2024

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights
2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Antiviral Drugs Market Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Antiviral Drugs: FDA Approvals and Patent Expiries by each drug class 
     4.9. Global relative prevalence rate of each hepatitis genotype infection
     4.10. Global relative prevalence rate of HIV infection
     4.11. Pipeline Analysis: Major Market Players

5. Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Disease Indication, 2014–2024
            5.4.1. Hepatitis Virus Infection
            5.4.2. HIV Infection
            5.4.3. Respiratory Virus Infection
            5.4.4. Others
     5.5. Market Attractiveness by Disease Indication 

6. Global Antiviral Drugs Market Analysis and Forecasts, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast by Product Type, 2014–2024
            6.4.1. Branded Drugs
            6.4.2. Generic Drugs
     6.5. Market Attractiveness by Product Type 

7. Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Distribution Channels, 2014–2024
            7.4.1. Hospital Pharmacy Store
            7.4.2. Retail Pharmacy Store
            7.4.3. Online Pharmacy
     7.5. Market Attractiveness by Distribution Channels 

8. Global Antiviral Drugs Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Forecast by Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness by Country/Region

9. North America Antiviral Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Key Trends
     9.2. Market Value Forecast by Disease Indication, 2014–2024
            9.2.1. Hepatitis Virus Infection
            9.2.2. HIV Infection
            9.2.3. Respiratory Virus Infection
            9.2.4. Others
     9.3. Market Value Forecast by Product Type, 2014–2024
            9.3.1. Branded Drugs
            9.3.2. Generic Drugs
     9.4. Market Value Forecast by Distribution Channels, 2014–2024
            9.4.1. Hospital Pharmacy Store
            9.4.2. Retail Pharmacy Store
            9.4.3. Online Pharmacy
     9.5. Market Value Forecast by Country, 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Disease Indication 
            9.6.2. By Product Type 
            9.6.3. By Distribution Channels 
            9.6.4. By Country

10. Europe Antiviral Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2. Market Value Forecast by Disease Indication, 2014–2024
            10.2.1. Hepatitis Virus Infection
            10.2.2. HIV Infection
            10.2.3. Respiratory Virus Infection
            10.2.4. Others
     10.3. Market Value Forecast by Product Type, 2014–2024
            10.3.1. Branded Drugs
            10.3.2. Generic Drugs
     10.4. Market Value Forecast by Distribution Channels, 2014–2024
            10.4.1. Hospital Pharmacy Store
            10.4.2. Retail Pharmacy Store
            10.4.3. Online Pharmacy
     10.5. Market Value Forecast by Country, 2014–2024
            10.5.1. U.K.
            10.5.2. Germany
            10.5.3. France
            10.5.4. Italy
            10.5.5. Spain
            10.5.6. Russia
            10.5.7. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. By Disease Indication 
            10.6.2. By Product Type 
            10.6.3. By Distribution Channels 
            10.6.4. By Country

11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Key Trends
     11.2. Market Value Forecast by Disease Indication, 2014–2024
            11.2.1. Hepatitis Virus Infection
            11.2.2. HIV Infection
            11.2.3. Respiratory Virus Infection
            11.2.4. Others
     11.3. Market Value Forecast by Product Type, 2014–2024
            11.3.1. Branded Drugs
            11.3.2. Generic Drugs
     11.4. Market Value Forecast by Distribution Channels, 2014–2024
            11.4.1. Hospital Pharmacy Store
            11.4.2. Retail Pharmacy Store
            11.4.3. Online Pharmacy
     11.5. Market Value Forecast by Country, 2014–2024
            11.5.1. India
            11.5.2. China
            11.5.3. Japan
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. By Disease Indication 
            11.6.2. By Product Type 
            11.6.3. By Distribution Channels 
            11.6.4. By Country

12. Latin America Antiviral Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Key Trends
     12.2. Market Value Forecast by Disease Indication, 2014–2024
            12.2.1. Hepatitis Virus Infection
            12.2.2. HIV Infection
            12.2.3. Respiratory Virus Infection
            12.2.4. Others
     12.3. Market Value Forecast by Product Type, 2014–2024
            12.3.1. Branded Drugs
            12.3.2. Generic Drugs
     12.4. Market Value Forecast by Distribution Channels, 2014–2024
            12.4.1. Hospital Pharmacy Store
            12.4.2. Retail Pharmacy Store
            12.4.3. Online Pharmacy
     12.5. Market Value Forecast by Country, 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Disease Indication 
            12.6.2. By Product Type 
            12.6.3. By Distribution Channels 
            12.6.4. By Country

13. Middle East and Africa Antiviral Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Key Trends
     13.2. Market Value Forecast by Disease Indication, 2014–2024
            13.2.1. Hepatitis Virus Infection
            13.2.2. HIV Infection
            13.2.3. Respiratory Virus Infection
            13.2.4. Others
     13.3. Market Value Forecast by Product Type, 2014–2024
            13.3.1. Branded Drugs
            13.3.2. Generic Drugs
     13.4. Market Value Forecast by Distribution Channels, 2014–2024
            13.4.1. Hospital Pharmacy Store
            13.4.2. Retail Pharmacy Store
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast by Country, 2014–2024
            13.5.1. South Africa
            13.5.2. GCC Countries
            13.5.3. Rest of Middle East and Africa
     13.6. Market Attractiveness Analysis 
            13.6.1. By Disease Indication 
            13.6.2. By Product Type 
            13.6.3. By Distribution Channels 
            13.6.4. By Country

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis by Company – 2016 (Estimated)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. AbbVie, Inc. 
                      14.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.1.2 Financial Overview
                      14.3.1.3 Product Portfolio
                      14.3.1.4 SWOT Analysis
                      14.3.1.5 Strategic Overview
            14.3.2. Bristol-Myers Squibb Company 
                      14.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.2.2 Financial Overview
                      14.3.2.3 Product Portfolio
                      14.3.2.4 SWOT Analysis
                      14.3.2.5 Strategic Overview
            14.3.3. Cipla, Inc. 
                      14.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.3.2 Financial Overview
                      14.3.3.3 Product Portfolio
                      14.3.3.4 SWOT Analysis
                      14.3.3.5 Strategic Overview
            14.3.4. F. Hoffmann-La Roche Ltd. 
                      14.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.4.2 Financial Overview
                      14.3.4.3 Product Portfolio
                      14.3.4.4 SWOT Analysis
                      14.3.4.5 Strategic Overview
            14.3.5. Gilead Sciences, Inc. 
                      14.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.5.2 Financial Overview
                      14.3.5.3 Product Portfolio
                      14.3.5.4 SWOT Analysis
                      14.3.5.5 Strategic Overview
            14.3.6. GlaxoSmithKline plc.
                      14.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.6.2 Financial Overview
                      14.3.6.3 Product Portfolio
                      14.3.6.4 SWOT Analysis
                      14.3.6.5 Strategic Overview
            14.3.7. Johnson & Johnson 
                      14.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.7.2 Financial Overview
                      14.3.7.3 Product Portfolio
                      14.3.7.4 SWOT Analysis
                      14.3.7.5 Strategic Overview
            14.3.8. Merck & Co., Inc. 
                      14.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.8.2 Financial Overview
                      14.3.8.3 Product Portfolio
                      14.3.8.4 SWOT Analysis
                      14.3.8.5 Strategic Overview
            14.3.9. Mylan N.V. 
                      14.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.9.2 Financial Overview
                      14.3.9.3 Product Portfolio
                      14.3.9.4 SWOT Analysis
                      14.3.9.5 Strategic Overview
            14.3.10. Teva Pharmaceutical Industries Ltd. 
                      14.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.10.2 Financial Overview
                      14.3.10.3 Product Portfolio
                      14.3.10.4 SWOT Analysis
                      14.3.10.5 Strategic Overview
            14.3.11. Others

List of Tables

Table 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 02: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 03: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 04: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 07: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 08: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 09: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 10: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 11: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 12: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 13: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 14: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 15: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 16: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 17: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 18: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 19: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 20: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 21: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 22: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 23: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 24: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024

List of Figures

Figure 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: FDA Approvals
Figure 03: FDA Approvals
Figure 04: FDA Approvals
Figure 05: FDA Approvals
Figure 06: FDA Approvals
Figure 07: FDA Approvals
Figure 08: FDA Approvals
Figure 09: FDA Approvals
Figure 10: HIV Prevalence
Figure 11: Hepatitis c virus prevalence
Figure 12: Pipeline Analysis
Figure 13: Global Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 14: Global Hepatitis Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 15: Global HIV Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 16: Global Respiratory Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 17: Global Other Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 18: Antiviral Drugs Market Attractiveness Analysis, Disease Indication, 2016–2024
Figure 19: Global Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 20: Global Branded Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 21: Global Generic Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 22: Antiviral Drugs Market Attractiveness Analysis, by Product, 2016–2024 
Figure 23: Global Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 24: Global Hospital Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 25: Global Retail Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 26: Global Online Pharmacy Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 27: Antiviral Drugs Market Attractiveness Analysis, by Distribution Channels, 2016–2024
Figure 28: Global Antiviral Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 29: Antiviral Drugs Market Attractiveness Analysis, by Region, 2016–2024
Figure 30: North America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 31: North America Market Attractiveness Analysis, by Country, 2016–2024
Figure 32: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: North America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 34: North America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 35: North America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 36: North America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 37: North America Market Attractiveness Analysis, by Product, 2016-2024
Figure 38: North America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 39: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Europe Market Attractiveness Analysis, by Country/ Region, 2016–2024
Figure 41: Europe Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 42: Europe Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 43: Europe Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 44: Europe Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 45: Europe Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 46: Europe Market Attractiveness Analysis, by Product, 2016-2024
Figure 47: Europe Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 48: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 49: Asia Pacific Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 50: Asia Pacific Market Value Share Analysis, by Country/ Region, 2016 and 2024
Figure 51: Asia Pacific Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 52: Asia Pacific Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 53: Asia Pacific Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 54: Asia Pacific Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 55: Asia Pacific Market Attractiveness Analysis, by Product, 2016-2024
Figure 56: Asia Pacific Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 57: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 58: Latin America Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 59: Latin America Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 60: Latin America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 61: Latin America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 62: Latin America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 63: Latin America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 64: Latin America Market Attractiveness Analysis, by Product, 2016-2024
Figure 65: Latin America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 66: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 67: MEA Market Attractiveness Analysis, by Country/ Region, 2016-2024
Figure 68: MEA Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 69: Middle East & Africa Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 70: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 71: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Product, 2016-2024
Figure 74: Middle East & Africa Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 75: Global Antiviral Drugs Market Share Analysis, by Company, (2015)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

631

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved